Fluorescein angiography is used in the routine clinical examination of patients with suspected retinopathy. Conventional angiography involves the photography of a subject's retina after injection with a small quantity of fluorescein dye. In this study, we have developed a technique to measure the movement of this dye through the retinal circulation. Two implementations of angiography have been investigated - conventional photography and capture of the angiographic frames using the scanning laser ophthalmoscope (SLO). After pre-processing to remove any noise present, the images are registered via cross-correlation to remove the effects of patient movement. A gamma variate plus 2nd order polynomial dye-dilution model is then fitted to the temporal change in fluorescein intensity at each point in the retina. Parameters are extracted from these fitted curves and their values combined to form functional images of the retinal circulation. A total of 16 angiograms of varying quality have been analysed using this technique. A distinctive filling pattern has been detected in the parametric images of the normal angiograms analysed, indicating a preferential flow of fluorescein, and hence blood, to the macula region of the retina. A number of abnormal angiograms were also analysed and the time to maximum images of these patients showed good agreement with their various pathologies. This included identifying occluded vessels, areas of ischaemia and oedema, as well as more subtle features such as leakage and microaneurysms. The generation of functional parametric images from fluorescein angiograms enables various aspects of the retinal circulation to be quantified. The technique offers a potential aid to diagnosis enabling the onset of retinopathy to be detected and its progression closely monitored.

No description available.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23813号 / 医博第4859号 / 新制||医||1059(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 中本 裕士, 教授 花川 隆, 教授 大森 孝一 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20986号 / 医博第4332号 / 新制||医||1027(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 富樫 かおり, 教授 羽賀 博典, 教授 別所 和久 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / Um estudo prospectivo, randomizado, duplo-cego, com grupos em paralelo e controle ativo foi conduzido para comparar os efeitos cardiovasculares da soluÃÃo aquosa de fenilefrina a 2,5% versus a 10% em pacientes diabÃticos do tipo 2, submetidos a angiografia fluoresceÃnica, e tambÃm para comparar a eficÃcia dessas soluÃÃes na dilataÃÃo pupilar. Os voluntÃrios foram atendidos no Hospital Santo InÃcio, em Juazeiro do Norte, CearÃ, e randomicamente alocados em dois grupos. Os pacientes no grupo A receberam uma gota de proximetacaÃna a 0,5%, de tropicamida a 1% e de fenilefrina a 2,5% em ambos os olhos, enquanto os do grupo B receberam proximetacaÃna a 0,5%, tropicamida a 1% e fenilefrina a 10%. A pressÃo arterial e a freqÃÃncia cardÃaca foram mensuradas cinco minutos antes e em vÃrios instantes apÃs a instilaÃÃo de fenilefrina no fÃrnice conjuntival ao longo de um perÃodo de trÃs horas. As alteraÃÃes no ritmo cardÃaco foram gravadas por uma unidade de Holter em todos os pacientes. A Ãrea pupilar foi calculada antes e sessenta minutos apÃs a instilaÃÃo de fenilefrina. Dos quarenta e trÃs pacientes envolvidos, 22 foram alocados no grupo A e 21, no grupo B. NÃo houve diferenÃa estatisticamente significante entre os grupos na mÃdia da pressÃo arterial sistÃlica apÃs a instilaÃÃo de fenilefrina. Essa observaÃÃo tambÃm foi vÃlida para todos os instantes em relaÃÃo à mÃdia da pressÃo diastÃlica, menos em um (150 minutos), onde o grupo da fenilefrina a 10% registrou valor mais alto (P = 0,0460). Um aumento significativo na mÃdia da pressÃo arterial (sistÃlica e diastÃlica - P < 0,001) foi igualmente verificado no momento da injeÃÃo endovenosa de fluoresceÃna nos dois grupos. NÃo se observou diferenÃa estatisticamente significante entre os grupos na mÃdia da freqÃÃncia cardÃaca. As mudanÃas no ritmo cardÃaco nÃo se relacionaram com o uso da fenilefrina em qualquer dos grupos. A magnitude da dilataÃÃo pupilar sessenta minutos apÃs o uso da fenilefrina nÃo foi diferente entre os grupos. Diante destes resultados, pÃde-se concluir que, apÃs uma Ãnica instilaÃÃo, a fenilefrina a 2,5% comparada à fenilefrina a 10% foi igualmente capaz de induzir e de manter adequada midrÃase em pacientes diabÃticos do tipo 2, submetidos a angiografia fluoresceÃnica. O aumento na pressÃo arterial que seguiu a injeÃÃo de fluoresceÃna, principal mudanÃa nos parÃmetros cardiovasculares analisados, provavelmente nÃo se relacionou diretamente com qualquer das concentraÃÃes de fenilefrina usadas / A prospective, randomized, double-blind study with groups in parallel and active control was conducted to compare the cardiovascular effects of aqueous solution of phenylephrine 2.5% versus 10% in diabetic type 2 patients undergoing fluorescein angiography, and also to compare their efficacy on pupillary dilation. The volunteers at the Santo InÃcio Hospital, in Juazeiro do Norte, Cearà were randomized into two groups. Patients in group A received one drop of 0.5% proxymetacaine, 1% tropicamide, and 2.5% phenylephrine in both eyes, whereas those in group B received 0.5% proxymetacaine, 1% tropicamide, and 10% phenylephrine. Blood pressure and heart rate were measured five minutes before and several times after phenylephrine eyedrop instillation for a period of three hours. Alterations in cardiac rhythm were recorded by Holter in all patients. Pupil surface was measured before and sixty minutes after phenylephrine instillation. Forty three patients were allocated into 22 patients (group A) and 21 patients (group B). There was no significant difference in the mean systolic blood pressure after phenylephrine instillation between the two groups. This observation was also valid for all but one instant where the mean diastolic blood pressure (150 minutes) was significantly higher in 10% phenylephrine group (P = 0.0460). A significant raise in mean systolic and diastolic blood pressure was registered at the moment of intravenous fluorescein injection in both groups (P < 0.001). No statistically significant difference was detected in the mean heart rate. Changes in cardiac rhythm could not be attributed to phenylephrine in either group. The amount of pupillary dilation at sixty minutes did not differ between the groups. In conclusion, after a single dose instillation, 2.5% phenylephrine compared to 10% phenylephrine was equally able to induce and keep adequate pupil dilation in diabetic type 2 patients undergoing fluorescein angiography. The raise in blood pressure following fluorescein injection was the main change observed in the cardiovascular parameters analyzed and probably did not relate to the use of any phenylephrine concentration

Thesis (doctoral)--Uppsala University, 1982. / Includes bibliographical references (p. 35-39).

Abstract Cardiac surgery with cardiopulmonary bypass (CPB) results in hemodilution, systemic inflammatory response, activation of coagulation and fibrinolysis, and microembolisation, which may all contribute to postoperative organ dysfunction. As an attempt to attenuate these side effects, the use of minimized cardiopulmonary bypass (MCPB) systems has increased. Compared to conventional CPB (CCPB), they are characterized with reduced artificial surface area and blood-air interface. The goal of these alterations has been to reduce systemic inflammation, preserve coagulation function and minimize the need for blood tranfusions. This study was aimed at determining whether or not MCPB attenuates the adverse effects of CPB. In study I, the safety, feasibility and effect on transfusion requirements of MCPB was investigated in unselected coronary artery bypass surgery (CABG) patients. In studies II and III, the incidence of retinal microembolism after CABG and aortic valve replacement (AVR) surgery with MCPB was compared to that of CCPB by means of fluorescein angiography. Furthermore, in studies II and III, the effect of MCPB on systemic inflammation, coagulation, endothelial activation and injury, as well as on platelet activity, was compared to those of CCPB. In study IV, the effect of MCPB on intestinal mucosal damage following CPB was compared to CCPB in a porcine model of prolonged CPB. MCPB appeared as safe and feasible as CCPB in unselected CABG patients (Study I). MCPB was associated with decreased retinal microembolism compared to CCPB in CABG patients (Study II). Conversely, the difference in retinal microembolism in AVR patients was not statistically significant (Study III). MCPB was associated with a decrease in neutrophil activation in CABG and AVR patients as compared to CCPB. However, there were no differences in coagulation, endothelial activation and injury, or in platelet activity (Studies II, III). There were no differences in markers of intestinal mucosal damage between MCPB and CCPB following prolonged CPB in the experimental model (Study IV). The results of this study suggest that MCPB may be used safely with CABG patients, with beneficial effects on hematocrit, and attenuated neutrophil activation. In CABG patients, MCPB is associated with reduced retinal microembolism, suggesting a decreased embolic load to the brain. The clinical feasibility of MCBP requires further technical evolution in the management of valve surgery. The results of the animal model support previous concerns regarding intestinal mucosal damage during CPB. / Tiivistelmä Sydänkeuhkokoneen käyttö aiheuttaa elimistössä hemodiluution, yleistyneen tulehdusvasteen ja hyytymisjärjestelmän aktivoitumisen sekä mikroembolisaatiota. Ilmiöt ovat yleensä lieviä ja ohimeneviä, mutta voivat johtaa elintoimintahäiriöihin ja pitkittyneeseen toipumiseen sydänleikkauksen jälkeen. Haittojen lievittämiseksi sydänkeuhkokonetta on pyritty kehittämään fysiologisemmaksi. Miniperfuusiolaitteistoissa kiertävän veren kontakti pintamateriaalien ja ilman kanssa jää pienemmäksi ja veren laimenemista tapahtuu vähemmän. Tutkimuksen tavoitteena oli selvittää voidaanko miniperfuusiolla lievittää sydänkeuhkokoneen haittoja. Ensimmäisessä osatyössä selvitettiin miniperfuusion käyttökelpoisuutta ja vaikutusta verensiirtotarpeeseen ohitusleikkauspotilailla valikoimattomassa aineistossa. Toisessa ja kolmannessa osatyössä selvitettiin silmänpohjan mikroembolioiden ilmaantuvuutta miniperfuusion ja perinteisen sydänkeuhkokoneen käytön jälkeen ohitusleikkauspotilailla ja aorttaläppäleikkauspotilailla. Toisessa ja kolmannessa osatyössä selvitettiin lisäksi miniperfuusion vaikutuksia yleistyneen tulehdusvasteen voimakkuuteen, hyytymisjärjestelmään sekä endoteelin aktivaatioon perinteiseen sydänkeuhkokoneeseen verrattuna. Neljännessä osatyössä verrattiin kokeellisessa mallissa miniperfuusion ja perinteisen sydänkeuhkokoneen vaikutuksia suoliston limakalvon eheyteen. Miniperfuusio ilmeni yhtä käyttökelpoiseksi kuin perinteinen sydänkeuhkokone ohitusleikkauspotilaiden hoidossa. Ohitusleikkauspotilailla ilmeni vähemmän silmänpohjan mikroembolioita miniperfuusion jälkeen, mutta aorttaläppäleikkauspotilailla ero ei ollut tilastollisesti merkitsevä. Miniperfuusion käyttöön liittyi vähemmän neutrofiilien aktivaatiota. Tekniikoiden välillä ei ilmennyt eroa hyytymisjärjestelmän eikä endoteelin aktivaatiota osoittavissa merkkiaineissa. Sydänkeuhkokoneen käyttö aiheutti saman tasoisen suoliston limakalvon vaurion miniperfuusiolla ja perinteisellä sydänkeuhkokoneella. Tutkimuksen perusteella miniperfuusiotekniikkaa voidaan käyttää turvallisesti ohitusleikkauspotilaiden hoidossa ja sen käyttö vähentää hemodiluutiota ja neutrofiilien aktivaatiota verrattuna perinteiseen sydänkeuhkokoneeseen. Miniperfuusiolla voidaan vähentää sydänkeuhkokoneen käytön aiheuttamaa silmänpohjan mikroembolisaatiota, joka saattaa viitata vähäisempään aivoverenkierron mikroembolisaatioon. Miniperfuusiotekniikoiden tulee edelleen kehittyä hyödyttämään enemmän myös aorttaläppäleikkauspotilaita. Löydökset koskien sydänkeuhkokoneen aiheuttamia suoliston limakalvovaurioita vahvistavat aiempaa olettamusta suoliston haavoittuvuudesta sydänleikkauksen jälkeen.